Arcutis Biotherapeutics (ARQT) Unveiled Fresh ZORYVE Data, Is The Stock Still Below Fair Value?

Simply Wall St.10-18 22:25

Arcutis Biotherapeutics (ARQT) is back in focus after new data from its ZORYVE portfolio, including Phase 2 infant atopic dermatitis results and psoriasis analyses, were presented at major dermatology...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2676469520?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","is_english":true,"pubTime":"2026-10-18 22:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2676469520","market":"us","top_or_hot":-1,"title":"Arcutis Biotherapeutics (ARQT) Unveiled Fresh ZORYVE Data, Is The Stock Still Below Fair Value?","media":"Simply Wall St.","content":"<div>\n<p>Arcutis Biotherapeutics (ARQT) is back in focus after new data from its ZORYVE portfolio, including Phase 2 infant atopic dermatitis results and psoriasis analyses, were presented at major dermatology...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-arqt-unveiled-fresh-zoryve-data-is-t\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcutis Biotherapeutics (ARQT) Unveiled Fresh ZORYVE Data, Is The Stock Still Below Fair Value?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcutis Biotherapeutics (ARQT) Unveiled Fresh ZORYVE Data, Is The Stock Still Below Fair Value?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-18 22:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-arqt-unveiled-fresh-zoryve-data-is-t><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arcutis Biotherapeutics (ARQT) is back in focus after new data from its ZORYVE portfolio, including Phase 2 infant atopic dermatitis results and psoriasis analyses, were presented at major dermatology...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-arqt-unveiled-fresh-zoryve-data-is-t\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-arqt-unveiled-fresh-zoryve-data-is-t","article_id":"2676469520","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-arqt-unveiled-fresh-zoryve-data-is-t","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2676469520","pubTimestamp":1792333530,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Arcutis Biotherapeutics (ARQT) is back in focus after new data from its ZORYVE portfolio, including Phase 2 infant atopic dermatitis results and psoriasis analyses, were presented at major dermatology meetings.\nThese fresh ZORYVE readouts arrive as Arcutis Biotherapeutics trades at US$28.82, with the 7-day share price return of 8.43% and 30-day share price return of 13.55% pointing to building momentum, while the 1-year total shareholder return of 38.03% and a very large 3-year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ARQT":"Arcutis Biotherapeutics Inc."},"translate_title":"Arcutis Biotherapeutics (ARQT) 公布了最新的 ZORYVE 数据，该股仍低于公允价值吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":1.5},"content_text":"Arcutis Biotherapeutics (ARQT) is back in focus after new data from its ZORYVE portfolio, including Phase 2 infant atopic dermatitis results and psoriasis analyses, were presented at major dermatology meetings. These fresh ZORYVE readouts arrive as Arcutis Biotherapeutics trades at US$28.82, with the 7-day share price return of 8.43% and 30-day share price return of 13.55% pointing to building momentum, while the 1-year total shareholder return of 38.03% and a very large 3-year total shareholder return signal that longer term investors have already seen substantial gains. Scan how other dermatology-focused and specialty biopharma stocks with real revenue and clinical catalysts line up by tracking our hand-picked 20 high quality undiscovered gems alongside Arcutis Biotherapeutics. Bulls see a fast-building dermatology franchise at Arcutis Biotherapeutics, while bears see recent gains outrunning fundamentals. Which side do the current numbers and valuation tilt toward next? AdvertisementMost Popular Narrative: 24.9% Undervalued Arcutis Biotherapeutics is framed as undervalued in the most widely followed narrative, with a fair value of $38.38 versus the recent $28.82 share price, and that view leans heavily on ZORYVE expansion and operating leverage.  Arcutis is poised to sustain and accelerate top-line revenue growth through continued expansion of ZORYVE indications, targeting large, underserved populations such as pediatric atopic dermatitis and scalp psoriasis, while leveraging broadening insurance coverage and the ongoing shift away from steroid use in chronic dermatologic conditions. The aging population and rising prevalence of chronic skin diseases, coupled with increased societal focus on wellness and early intervention, are driving long-term demand and patient growth for innovative non-steroidal treatments, which are well aligned with ZORYVE's differentiated safety profile and underpin sustained revenue expansion.  See why 34 investors see Arcutis Biotherapeutics as 25% undervalued. Result: Fair Value of $38.38 (UNDERVALUED) Still, the whole Arcutis Biotherapeutics story leans heavily on ZORYVE, so any setback in prescriptions or payer coverage could quickly challenge that 24.9% undervalued narrative. Find out about the key risks to this Arcutis Biotherapeutics narrative. Another View: Arcutis Biotherapeutics Looks Expensive On Earnings The DCF work paints Arcutis Biotherapeutics as cheap, yet the market is paying a P/E of 127x, compared with 17.4x for the US Biotechs industry and a fair ratio of 33.2x. That gap points to real valuation risk if growth or sentiment cools even slightly. For a closer look at how this earnings multiple stacks up against peers and the fair ratio that models suggest the market could move toward, See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:ARQT P/E Ratio as at Oct 2026Next Steps Mixed signals around Arcutis Biotherapeutics can be hard to read, so act promptly, review the full risk and reward breakdown, and judge it for yourself with 4 key rewards and 1 important warning sign Looking for more ideas beyond Arcutis Biotherapeutics? If Arcutis Biotherapeutics has your attention, do not stop there. Broadening your watchlist now can sharpen your edge before the next catalyst hits.  Target resilient cash generators by reviewing a list of solid balance sheet and fundamentals (25 results) that keeps financial strength front and center when markets turn choppy. Hunt for mispriced quality by scanning a curated 33 high quality undervalued stocks that filters for fundamentals instead of headline noise. Build a smoother ride for your portfolio through a 32 resilient stocks with low risk scores that screens for businesses with more stable risk profiles.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2676469520","isCrawlerRequest":true}